Press Release Archives
Precipio Inc
Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE.

Precipio Inc Press Releases

Press Archives

Precipio Inc

Press Archives

Precipio CEO enrolls in long term stock purchase plan

May 23rd 2019

Precipio Regains Nasdaq Listing Compliance

May 15th 2019

Precipio Conducts IV-Cell™ Validation Trial with a Prominent Laboratory

May 6th 2019

May 6, 2019 NEW HAVEN, Conn., May 06, 2019 -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it is in the process of complet

Precipio Successfully Completes Nasdaq Hearing Process

May 3rd 2019

Company is expected to regain listing compliance upon completion of the remaining 10-day requirement

Precipio Reminder of Corporate Update Shareholder Call

May 1st 2019

Conference Call to be held Monday May 6th, 2019 at 5:00pm Eastern Time

Precipio Signs First Major International Services Contract

Apr 29th 2019

Contract expected to generate over $1.5M in revenues annually

Precipio Takes Final Step towards Regaining Nasdaq Compliance

Apr 26th 2019

Company announces 1-for-15 reverse stock split

Precipio Launches Global Expansion Strategy

Apr 24th 2019

Precipio to capitalize on powerful data and expertise to grow business globally

Mr. Ori Karev Joins Precipio Executive Team As Chief Strategy Officer

Apr 18th 2019

Precipio to expand its reach globally

Precipio Announces 2018 Year-End Corporate Update Call for Shareholders

Apr 15th 2019

Conference Call to Be Held On Monday, May 6th, 2019 at 5:00 PM ET

Precipio Identifies Manufacturer for its IV-Cell Media

Apr 9th 2019

Manufacturing Partner enables Precipio to address customer demand and plans for global distribution

Precipio’s HemeScreen™ Adopted by Methodist Health

Apr 3rd 2019

New Molecular Screening Assay Technology Gains Traction